Chimeric: Media Thread, page-607

Milcom, I don't know about your expertise in that GBM field but let's assume you are an expert. Therefore you should understand that, as the FDA has signaled to CHM to go for a rego trial, the data are sufficient to warrant that step. And therefore I value the FDA's invitation for CHM higher than your opinion.

The sp has suffered due to unfavourable market conditions and highly questionable funding decisions ( CR and Lind ). But the science has progressed really well and that is what will count in the end. Yes, you can argue the team is overpaid, underqualified or whatever. But the data of all platforms so far have exceeded expectations.

GLTA